|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||62.97 - 65.29|
|52-week range||43.11 - 72.61|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||N/A|
|Earnings date||02 Aug 2021 - 06 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||73.50|
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the appointment of Daniel J. Wolterman as independent chair of the NuVasive Board of Directors, effective immediately. Mr. Wolterman succeeds Gregory T. Lucier as the Company's Board chair, following Mr. Lucier's retirement from the Board on May 18, 2021.
Despite strong share price growth of 40% for NuVasive, Inc. ( NASDAQ:NUVA ) over the last few years, earnings growth...